Since February 2016, my PCR test results for CML have been “not detected”, and my blood counts are pretty much in the normal range. My oncologist is pleased (as am I). I am still on 300mg of imatinib, and thus far, he strenuously objects to a further reduction in my dose.
My biggest issue now is the cost of the drug. I am now retired and have a Medicare health insurance plan. Medicare does not negotiate drug prices, so I have paid much more than I did when I had a plan through my employer. Imatinib – the generic version of Gleevec – is not that much cheaper than the name brand, though there are rumors of an upcoming price drop (yes, please!). I’m hoping that our government can get their act together and address Medicare drug prices. I continue to contact my senators and congressman on the issue.
You must be logged in to post a comment.